BMI and Sleep Apnea: Evaluating the Role of Weight, Aging, and Gender in OSA Severity and Hypoxic Burden

Dr. Chelsie Rohrscheib, PhD 
Head Sleep Expert & Neuroscientist 
February 12, 2025 

With the advent of GLP-1 receptor agonists as a transformative approach to weight management, it is essential to understand how medically induced weight loss affects obstructive sleep apnea (OSA) severity. As obesity remains a key risk factor for OSA, further investigation is needed to clarify the independent effects of body mass index (BMI), age, and gender on OSA severity. To address this, we analyzed two datasets: a mixed BMI cohort consisting of 722 Wesper Lab patients and a separate obese to a morbidly obese cohort of 642 patients. Multiple linear regression models revealed that in the mixed dataset, BMI was significantly associated with higher apnea-hypopnea index (AHI) and hypoxic burden (HB, %min/hr), with each additional BMI unit increasing AHI by 1.01 events/hour and HB by 2.71% per hour. In the obese-only cohort, BMI had a slightly weaker effect on AHI but a stronger association with age and male gender. Males in the obese group experienced 39.1% greater HB compared to 31.5% in the mixed dataset, highlighting the progressive impact of obesity on OSA severity. These findings underscore the importance of evaluating whether GLP-1-induced weight loss, in combination with traditional OSA therapies, can mitigate disease severity and improve patient outcomes.

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by recurrent episodes of upper airway obstruction, leading to disrupted sleep and intermittent hypoxia ¹ . Obesity is a well-established risk factor for OSA2, yet the relative contributions of body mass index (BMI), age, and gender to disease severity remain an area of ongoing research. Understanding these relationships is crucial for optimizing treatment strategies, particularly as new weight loss therapies, such as GLP-1 receptor agonists ³ , become more widely available.

Given the strong association between obesity and OSA, it is critical to evaluate how pharmacologically induced weight loss might influence apnea/hypopnea index (AHI) and hypoxic burden (HB, %min/hr), two metrics used to assess sleep apnea severity ⁴ . This study compares two distinct patient cohorts—a mixed BMI population and an obese-only group—to determine whether the relationships between BMI, age, and gender with OSA severity differ between populations and to assess the potential implications of GLP-1 therapy in mitigating disease burden.

This cross-sectional study analyzed two Wesper Lab home sleep apnea test datasets: a mixed BMI cohort of 722 patients (Males: 445, Females: 277, Mean Age: 47.68 (SD: 13.28), Mean BMI: 33.05 (SD: 7.75)), and a separate obese-only cohort of 642 patients (Males: 151, Females: 491, Mean Age: 40.44 (SD: 10.82), Mean BMI: 41.80 (SD: 7.21)). Patient demographics, BMI, age, gender, AHI, and HB were extracted for analysis. The mixed dataset included individuals across a range of BMI values, whereas the obese-only cohort consisted exclusively of individuals with BMI ≥ 30.

Multiple linear regression models were used to examine associations between BMI, age, and gender with AHI and HB in both datasets. The strength of these relationships was compared between groups to assess whether obesity alters the predictive impact of these factors. Statistical significance was set at p < 0.05, with 95% confidence intervals (CI) reported for all estimates.

In the mixed dataset, AHI increased by 1.01 events per hour for each unit increase in BMI (p < 0.001, 95% CI: 0.83–1.19, Figure 1A), while each additional year of age contributed 0.32 more events per hour (p < 0.001, 95% CI: 0.21–0.43). Males had significantly higher AHI than females, averaging 9.15 more events per hour (p < 0.001, 95% CI: 6.25–12.06). HB increased by 2.71% per hour per BMI unit (p < 0.001, 95% CI: 2.05–3.37, Figure 2A), and age added 0.67% per hour (p = 0.001, 95% CI: 0.29–1.05). Males exhibited 31.5% greater HB compared to females (p < 0.001, 95% CI: 21.09–41.92).

In the obese-only dataset, BMI had a slightly weaker effect on AHI (β = 0.94, p < 0.001, 95% CI: 0.64–1.24, Figure 1C), while age had a stronger association (β = 0.38, p < 0.001, 95% CI: 0.22–0.54). Gender disparities were more pronounced in the obese group, with males experiencing 10.82 more AHI events per hour than females (p < 0.001, 95% CI: 7.19–14.45). HB also increased with BMI (β = 2.54, p < 0.001, 95% CI: 1.89–3.19, Figure 1D) and age (β = 0.79, p = 0.002, 95% CI: 0.31–1.27), with males experiencing 39.1% greater HB than females (p < 0.001, 95% CI: 28.76–49.44).

Figure 1: The effect of BMI on the Apnea/Hypopnea Index (AHI) and Hypoxic Burden (HB). A) BMI vs. AHI in the mixed BMI population. B) BMI vs. AHI in the obese population. C) BMI vs. HB in the mixed BMI population. D) BMI vs. HB in the obese population.

These findings suggest that while BMI remains a key determinant of OSA severity, its effect diminishes slightly in severe obesity, whereas age and gender disparities become more pronounced. The stronger associations observed for age and gender in the obese group emphasize the need for targeted interventions beyond weight loss alone.

While GLP-1 receptor agonists represent a promising advancement in weight management and may contribute to reductions in OSA severity, they are unlikely to be a standalone solution, particularly for individuals with obesity. This study demonstrated that BMI, age, and male gender are strong predictors of OSA severity, with more pronounced effects in the obese-only group. Although BMI remained a significant factor, its impact on AHI appeared to plateau in obesity, while age and gender had even stronger associations, suggesting that additional physiological factors—such as airway collapsibility and fat distribution—contribute to disease progression.

Given these findings, a multimodal approach integrating GLP-1 therapy with traditional OSA interventions—such as continuous positive airway pressure (CPAP), mandibular advancement devices, and lifestyle modifications—may be necessary for optimal patient outcomes. While pharmacologically induced weight loss may reduce AHI and HB, it may not fully address residual airway obstruction, particularly in individuals with severe OSA. CPAP remains the gold standard treatment, ensuring airway patency regardless of weight status. Future research should explore the long-term impact of GLP-1 therapy in conjunction with established interventions to develop personalized treatment strategies tailored to obese individuals with OSA, thereby improving disease management and patient quality of life.

1. How does BMI impact obstructive sleep apnea (OSA) severity?

BMI is a key risk factor for OSA, with higher BMI values associated with increased apnea-hypopnea index (AHI) and hypoxic burden (HB). In the mixed BMI cohort, each additional BMI unit increased AHI by 1.01 events per hour and HB by 2.71% per hour. However, in severe obesity, the effect of BMI on AHI slightly diminishes, suggesting additional physiological factors contribute to OSA severity.

2. Does weight loss improve sleep apnea symptoms?

Weight loss, including that induced by GLP-1 receptor agonists, may help reduce OSA severity by lowering AHI and HB. However, weight loss alone may not fully resolve airway obstruction, especially in individuals with severe OSA. A combination of treatments, such as CPAP therapy and lifestyle modifications, may be necessary for optimal management.

3. How do age and gender influence OSA severity?

Age and male gender are significant predictors of OSA severity. In both study cohorts, older individuals and males exhibited higher AHI and HB. In the obese-only group, males experienced 39.1% greater HB compared to females, highlighting the progressive impact of obesity on gender-related disparities in OSA severity.

4. What role do GLP-1 receptor agonists play in managing OSA?

GLP-1 receptor agonists are primarily used for weight management and may help reduce OSA severity by lowering BMI. However, this study suggests that while weight loss may improve symptoms, it is unlikely to be a standalone solution for OSA. Integrating GLP-1 therapy with traditional interventions, such as CPAP or mandibular advancement devices, may provide better outcomes.

5. Why does BMI have a weaker effect on AHI in the obese-only group?

In individuals with severe obesity, the effect of BMI on AHI appears to plateau, meaning other factors—such as fat distribution, airway collapsibility, and muscle tone—may play a more significant role in OSA severity. This suggests that simply reducing BMI may not fully mitigate the condition in patients with higher baseline obesity.

6. What are the best treatment strategies for individuals with obesity and OSA?

A multimodal approach is recommended, incorporating weight management strategies (such as GLP-1 therapy or lifestyle changes) with standard OSA treatments like CPAP, positional therapy, and mandibular advancement devices. Addressing age- and gender-related differences may also help tailor treatment for better patient outcomes.

Would you like me to refine or expand any section further?

1. Abbasi A, Gupta SS, Sabharwal N, Meghrajani V, Sharma S, Kamholz S, Kupfer Y. A comprehensive review of obstructive sleep apnea. Sleep Sci. 2021 Apr-Jun;14(2):142-154. doi: 10.5935/1984-0063.20200056.
2. Messineo L, Bakker JP, Cronin J, Yee J, White DP. Obstructive sleep apnea and obesity: A review of epidemiology, pathophysiology and the effect of weight-loss treatments. Sleep Med Rev. 2024 Dec;78:101996. doi: 10.1016/j.smrv.2024.101996. Popoviciu MS, Păduraru L, Yahya G, Metwally K, Cavalu S. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci. 2023 Jun 21;24(13):10449. doi: 10.3390/ijms241310449.
3. Popoviciu MS, Păduraru L, Yahya G, Metwally K, Cavalu S. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci. 2023 Jun 21;24(13):10449. doi: 10.3390/ijms241310449.
4. Martinez-Garcia MA, Sánchez-de-la-Torre M, White DP, Azarbarzin A. Hypoxic Burden in Obstructive Sleep Apnea: Present and Future. Arch Bronconeumol. 2023 Jan;59(1):36-43. English, Spanish. doi: 10.1016/j.arbres.2022.08.005.